TY  - JOUR
AU  - Zeitler, Magteld
AU  - Tass, Peter A.
TI  - Anti-kindling Induced by Two-Stage Coordinated Reset Stimulation with Weak Onset Intensity
JO  - Frontiers in computational neuroscience
VL  - 10
SN  - 1662-5188
CY  - Lausanne
PB  - Frontiers Research Foundation
M1  - FZJ-2016-05017
SP  - 44
PY  - 2016
AB  - Abnormal neuronal synchrony plays an important role in a number of brain diseases. To specifically counteract abnormal neuronal synchrony by desynchronization, Coordinated Reset (CR) stimulation, a spatiotemporally patterned stimulation technique, was designed with computational means. In neuronal networks with spike timing–dependent plasticity CR stimulation causes a decrease of synaptic weights and finally anti-kindling, i.e., unlearning of abnormally strong synaptic connectivity and abnormal neuronal synchrony. Long-lasting desynchronizing aftereffects of CR stimulation have been verified in pre-clinical and clinical proof of concept studies. In general, for different neuromodulation approaches, both invasive and non-invasive, it is desirable to enable effective stimulation at reduced stimulation intensities, thereby avoiding side effects. For the first time, we here present a two-stage CR stimulation protocol, where two qualitatively different types of CR stimulation are delivered one after another, and the first stage comes at a particularly weak stimulation intensity. Numerical simulations show that a two-stage CR stimulation can induce the same degree of anti-kindling as a single-stage CR stimulation with intermediate stimulation intensity. This stimulation approach might be clinically beneficial in patients suffering from brain diseases characterized by abnormal neuronal synchrony where a first treatment stage should be performed at particularly weak stimulation intensities in order to avoid side effects. This might, e.g., be relevant in the context of acoustic CR stimulation in tinnitus patients with hyperacusis or in the case of electrical deep brain CR stimulation with sub-optimally positioned leads or side effects caused by stimulation of the target itself. We discuss how to apply our method in first in man and proof of concept studies.
LB  - PUB:(DE-HGF)16
UR  - <Go to ISI:>//WOS:000375840700001
C6  - pmid:27242500
DO  - DOI:10.3389/fncom.2016.00044
UR  - https://juser.fz-juelich.de/record/819316
ER  -